NasdaqCM:SLNOBiotechs
Do Ongoing DCCR Lawsuits Reframe Soleno Therapeutics’ (SLNO) Risk Profile More Than Its Drug Potential?
In recent months, Soleno Therapeutics has faced multiple securities class action lawsuits alleging that the company and certain executives failed to disclose material safety concerns and data integrity issues tied to the Phase 3 program for its Prader‑Willi syndrome drug DCCR, marketed as VYKAT XR.
These legal challenges, centered on claims of undisclosed risks such as fluid retention, diabetes‑related markers, and high discontinuation rates, have intensified scrutiny of VYKAT XR’s clinical...